Market Overview

Morning Market Movers

Related NBIX
Benzinga's Volume Movers
Morning Market Gainers
Neurocrine Tardive Dyskinesia Drug Hits, Stock Jumps (Investor's Business Daily)
Related EPZM
Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now
Epizyme Updated Tazemetostat Phase 1 Data Show Clinical Activity in a Broader Range of Adults With INI1-Negative and SMARCA4-Negative Solid Tumors

Neurocrine Biosciences (NASDAQ: NBIX) jumped 60.40% to $15.66 after the company reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study.

Epizyme (NASDAQ: EPZM) moved up 55.32% to $31.84 after the company reported two major milestone achievements. It announced the achievement of a proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program.

Verso Paper (NYSE: VRS) rose 31.70% to $4.23 after the company announced its plans to acquire NewPage for $1.4 billion.

Stereotaxis (NASDAQ: STXS) shares jumped 19.26% to $4.77 after the company Stereotaxis completed the clinical trial of Vdrive with V-Loop.

Posted-In: market moversNews Intraday Update Markets Movers


Related Articles (NBIX + EPZM)

View Comments and Join the Discussion!

Get Benzinga's Newsletters